Jim B D Keijser

Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases

P. van Paassen, A. ten Brinke, G. D'Haens, 2022, Annals of the Rheumatic Diseases.

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

S. Nejentsev, C. Allaart, W. Lems, 2022, The Lancet Rheumatology.

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

R. R. Hagen, S. Nejentsev, P. van Paassen, 2022, The Lancet Rheumatology.

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

W. Lems, M. Boers, C. Wijbrandts, 2022, RMD Open.

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations

P. van Paassen, F. Bemelman, G. D'Haens, 2023, Journal of Autoimmunity.